Sheila K Pierson

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 9

Top Topics

Newly Diagnosed

Top Venues

American journal of hematology

Journal of cellular and molecular medicine

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Natalie A Mango, Sheila K Pierson, Mateo Sarmiento Bustamante, Joshua D Brandstadter, Frits Van Rhee, David C Fajgenbaum
Siltuximab administration results in spurious IL-6 elevation in peripheral blood. American journal of hematology (2023)
Sheila K Pierson, Megan S Lim, Gordan Srkalovic, Joshua D Brandstadter, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Natalie Mango, Criswell Lavery, Bridget Austin, Daisy Alapat, Mary Jo Lechowicz, Adam Bagg, Honzhe Li, Corey Casper, Frits van Rhee, David C Fajgenbaum
Treatment Consistent with Idiopathic Multicentric Castleman Disease Guidelines is Associated with Improved Outcomes. Blood advances (2023)
Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Freda R Coren, Adam Bagg, Gordan Srkalovic, Daisy Alapat, Frits Van Rhee, Megan S Lim, Mary Jo Lechowicz, Joshua D Brandstadter, Sheila K Pierson, David C Fajgenbaum
Ongoing symptoms following complete surgical excision in unicentric Castleman disease. American journal of hematology (2023)
Sheila K Pierson, Laura Katz, Reece Williams, Melanie D Mumau, Michael Gonzalez, Stacy Guzman, Ayelet Rubenstein, Ana B Oromendia, Philip Beineke, Alexander Fosså, Frits Van Rhee, David C Fajgenbaum
CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease. Nature communications 13 (1) (2022)
Elizaveta Belyaeva, Ayelet Rubenstein, Sheila K Pierson, Delaney Dalldorf, Dale M Frank, Megan S Lim, David C Fajgenbaum
Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review. Hematological oncology 40 (2) (2022)
Alexis D Phillips, Joseph J Kakkis, Patricia Y Tsao, Sheila K Pierson, David C Fajgenbaum
Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO. Journal of cellular and molecular medicine 26 (11) (2022)
David C Fajgenbaum, Sheila K Pierson, Karan Kanhai, Adam Bagg, Daisy Alapat, Megan S Lim, Mary Jo Lechowicz, Gordan Srkalovic, Thomas S Uldrick, Frits van Rhee, null null
The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry. British journal of haematology 198 (2) (2022)
Sheila K Pierson, Sushila Shenoy, Ana B Oromendia, Alexander M Gorzewski, Ruth-Anne Langan Pai, Christopher Shield Nabel, Jason R Ruth, Sophia A T Parente, Daniel J Arenas, Mary Guilfoyle, Manjula Reddy, Michael Weinblatt, Nancy A Shadick, Mark Bower, Alessia Dalla Pria, Yasufumi Masaki, Laura Katz, Jason Mezey, Philip Beineke, David Lee, Craig Tendler, Taku Kambayashi, Alexander Fosså, Frits van Rhee, David C Fajgenbaum
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. Blood advances 5 (17) (2021)
Yoshito Nishimura, David C Fajgenbaum, Sheila K Pierson, Noriko Iwaki, Asami Nishikori, Mitsuhiro Kawano, Naoya Nakamura, Koji Izutsu, Kengo Takeuchi, Midori Filiz Nishimura, Yoshinobu Maeda, Fumio Otsuka, Kazuyuki Yoshizaki, Eric Oksenhendler, Frits Van Rhee, Yasuharu Sato
Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. American journal of hematology 96 (10) (2021)